Features
Nuclear Medicine department and PET center of CSMUH were founded in 1988. Our department has the contemporarily latest imaging equipment, including two sets of integrated single photon emission computerized tomography-computerized tomography scanner (SPECT-CT, GE Discovery NM/CT 670 CZT and GE Discovery NM/CT 860 ), two sets of integrated positron emission tomography-computed tomography scanner (PET/CT, GE Discovery MI), a dual-energy X-ray absorptiometry (Hologic Discovery Wi), and a gamma counter for radioimmunoassay. The radioisotope therapy unit also had been completed construction and provided hospitalization service since May 27, 2019. All devices have a good maintenance plan and quality assurance programs to ensure the service quality. Our team, consisting of experienced physicians and well-trained healthcare professionals, have provided trustworthy medical service for people in middle Taiwan for more than 35 years.
Medical Service
- Conventional nuclear medicine imaging: whole body bone scan, single photon emission computerized tomography of myocardial perfusion scan, single photon emission computerized tomography of brain perfusion imaging, single photon emission computerized tomography of dopamine transporter imaging (Trodat-1), whole body tumor scan, lung perfusion scan, lung ventilation scan, single photon emission computed tomography scan of renal cortex imaging, effective renal blood flow analysis , semi-quantitative salivary gland scan, gastrointestinal motor function scan, radionuclide thyroid scan, single photon emission computed tomography scan of parathyroid imaging, adrenal (cortical and medullary) imaging, whole body inflammation scan (gallium-67).
- Positron emission tomography- computed tomography scan: Whole body FDG oncologic imaging, FDG myocardial viability study, and FLT whole body oncologic imaging.
- Radioimmunoassay: 20 radioimmunoassay test items, including the endocrine system and tumor markers.
- Radionuclide therapy: radioiodine treatment for differentiated thyroid cancer; radioligand therapy for metastatic prostate cancer; and peptide receptor radionuclide therapy for unresectable/metastatic neuroendocrine tumor .
- Dual-energy X-ray absorptiometry: bone density measurement and body composition analysis.
Future Perspectives
- Growth of amount of clinical service
- Introduction of new target radiotherapies
- Clinical trials in the test of novel PET radiopharmaceuticals
- Training of residents, PGY, internship of radiographers, and exchange students